ANRO (Alto Neuroscience) ROCE %: -47.09% (As of Mar. 2026)


ANRO Alto Neuroscience Inc ANRO
12 GF Score
Price $25.30
! 1 Warning Sign
View Full Analysis

What is Alto Neuroscience ROCE %?

Alto Neuroscience ANRO +1.57% 12 ROCE % is -47.09% as of Mar. 2026. GuruFocus rates ANRO with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Alto Neuroscience's annualized ROCE % for the quarter that ended in Mar. 2026 was -47.09%.

Alto Neuroscience  (NYSE:ANRO) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Alto Neuroscience ROCE % Related Terms

Alto Neuroscience ROCE % Historical Data

* Premium members only.

The historical data trend for Alto Neuroscience's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alto Neuroscience ROCE % Chart

Alto Neuroscience Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
-33.66 -76.68 -55.32 -48.32 -35.65

Alto Neuroscience Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -35.09 -43.41 -37.62 -40.10 -47.09
ANRO
12GF Score
Alto Neuroscience Inc ANRO
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alto Neuroscience ROCE % Calculation

Alto Neuroscience's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-60.769/( ( (177.542 - 10.008) + (184.689 - 11.325) )/ 2 )
=-60.769/( (167.534+173.364)/ 2 )
=-60.769/170.449
=-35.65 %

Alto Neuroscience's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-102.768/( ( (184.689 - 11.325) + (276.259 - 13.115) )/ 2 )
=-102.768/( ( 173.364 + 263.144 )/ 2 )
=-102.768/218.254
=-47.09 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -47.09% mean?
Alto Neuroscience (ANRO) has a ROCE % of -47.09% as of Mar. 2026.
Is Alto Neuroscience's ROCE % too high?
Alto Neuroscience's current ROCE % is -47.09%. Overall, Alto Neuroscience has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Alto Neuroscience's ROCE % compare to MRVI and BBOT?
Alto Neuroscience's ROCE % of -47.09% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Alto Neuroscience's current ROCE % is -47.09%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alto Neuroscience stock overvalued right now?
Alto Neuroscience (ANRO) has a current ROCE % of -47.09%. The current ROCE % is -47.09%. Alto Neuroscience's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Alto Neuroscience (ANRO), the current ROCE % is -47.09% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Alto Neuroscience Business Description

Address 650 Castro Street, Suite 450, Mountain View, CA, USA, 94041
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
12GF Score

Get the complete analysis for ANRO

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$25.30
Price